Y Nonagase

Learn More
BACKGROUND We evaluated the safety, maximum-tolerated dose (MTD), pharmacokinetics, recommended dose for phase II (P2RD), and preliminary anticancer activity of a combination eribulin and S-1 therapeutic in metastatic breast cancer patients pretreated with anthracycline and taxane. METHOD Patients aged 20-74 years were recruited. In level 1, patients(More)
  • 1